Avodart Cost in Maine 2026: Dutasteride Prices, Insurance, and Savings

What Does Avodart Actually Cost in Maine in 2026?

Generic dutasteride 0.5 mg oral capsules cost approximately $25 per month at Maine retail pharmacies when purchased with a GoodRx-style discount card or through a 90-day mail-order program. Brand-name Avodart carries a manufacturer list price near $290 per month, a figure almost no cash-paying patient needs to accept given the availability of generics that the FDA confirmed as therapeutically equivalent. [1]

Dutasteride went off-patent in the United States in 2015, and multiple FDA-approved generic manufacturers now supply the 0.5 mg capsule. The FDA's Orange Book lists these generics as AB-rated, meaning they are bioequivalent to Avodart and may be substituted by Maine pharmacists under Maine Revised Statutes Title 32, Section 13781, which requires generic substitution unless the prescriber writes "brand medically necessary." [2]

Price varies by pharmacy. A 30-day supply at a large chain (CVS, Walgreens, Walmart) in Portland or Bangor typically ranges from $20 to $35 without insurance when a discount coupon is applied. Independent pharmacies in rural Maine may charge more or less depending on their wholesaler contracts. The single most reliable strategy is to check GoodRx or NeedyMeds prices for your specific ZIP code before filling. [3]

The FDA's 5-alpha reductase inhibitor class label for dutasteride, the same mechanism that suppresses dihydrotestosterone (DHT) by inhibiting both type 1 and type 2 5-alpha reductase isoenzymes, has not changed since approval in 2001. DHT suppression of roughly 90% to 95% at the 0.5 mg dose is the pharmacological basis for both BPH symptom relief and hair-loss treatment. [4]

Does MaineCare (Maine Medicaid) Cover Dutasteride?

MaineCare covers dutasteride for the FDA-approved indication of benign prostatic hyperplasia with a prior authorization (PA) request. The PA process requires the prescribing clinician to document a confirmed BPH diagnosis, symptom burden (typically an AUA symptom score of 8 or higher), and that alpha-blocker monotherapy has been trialed or is contraindicated. [5]

Off-label coverage for androgenetic alopecia under MaineCare is not guaranteed. Claims submitted for hair loss are frequently denied on the basis that the indication is cosmetic, though individual reconsideration and appeal are available. A prescriber who can document the medical necessity of treatment in cases where hair loss is associated with a documented endocrine or dermatologic condition may have a stronger appeal argument. [6]

For patients who qualify, MaineCare's pharmacy benefit covers the generic formulation at the applicable co-pay tier, which for most fee-for-service MaineCare enrollees in 2026 is $3.65 per prescription for preferred generics. MaineCare managed care plans (administered by Anthem and WellCare in Maine) may have slightly different PA criteria and co-pay structures, so enrollees should confirm with their specific plan. [7]

Prescribers submit PA requests through Maine's MIHMS (Maine Integrated Health Management Solution) portal. Approvals are typically returned within 72 hours for standard requests and within 24 hours for expedited requests when clinical urgency is documented. [8]

Which Private Insurance Plans Cover Avodart in Maine?

Most commercial insurance plans in Maine cover generic dutasteride on Tier 1 or Tier 2 of the formulary, resulting in co-pays from $0 to $15 per 30-day fill. Brand-name Avodart, when still prescribed, lands on Tier 3 or Tier 4, with co-pays of $40 to $100 or higher depending on the plan design. [9]

The three largest commercial carriers operating in Maine in 2026 are Anthem Blue Cross Blue Shield, Harvard Pilgrim Health Care, and Aetna. All three list generic dutasteride as a covered drug for BPH without PA on most standard formularies. The ACA marketplace plans offered through CoverME.gov follow the same formulary structures. [10]

Step therapy is occasionally required: some plans mandate a trial of an alpha-1 blocker such as tamsulosin (Flomax) 0.4 mg before approving dutasteride, particularly for BPH. The 4-year MTOPS trial (N=3,047) provided evidence that combination therapy with doxazosin plus finasteride reduced clinical progression of BPH more than either drug alone, which is part of why guidelines allow but do not universally require combination approaches before 5-ARI approval. [11]

For the AvodartPlus savings card (GSK), eligibility in Maine requires commercial insurance. Patients on government programs including MaineCare, Medicare Part D, or Tricare are not eligible. The card can bring out-of-pocket costs to as low as $0 per month for commercially insured patients whose plan covers Avodart, though it does not apply to generic fills. Check the current GSK savings card terms directly at GSK's patient support portal, as income thresholds and monthly caps change annually. [12]

Medicare Part D covers generic dutasteride on most plans' Tier 1 or Tier 2, with a typical 2026 co-pay of $5 to $10 per month during the deductible-met phase. The Medicare Prescription Payment Plan (formerly catastrophic cap changes under IRA 2022) may further reduce costs for high-spending beneficiaries. [13]

Is Compounded Dutasteride Legal in Maine?

Compounded dutasteride is legal in Maine when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed Maine prescriber. The FDA does not prohibit compounding of dutasteride because it does not appear on the FDA's list of drugs that are essentially a copy of a commercially available product in a context where the compounder claims a clinical difference. [14]

503A pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act and must comply with both FDA regulations and Maine Board of Pharmacy rules (Maine Rules Governing the Practice of Pharmacy, Chapter 2). A 503A pharmacy dispenses only patient-specific prescriptions; it cannot manufacture large batches for general distribution without upgrading to 503B outsourcing facility status. [15]

The typical compounded formulation for hair loss is a topical solution containing dutasteride 0.25% to 0.5% in an ethanol-based vehicle, often combined with minoxidil 5% to 10%. For oral use, compounded capsules replicating the 0.5 mg commercial dose are also prepared, though pharmacoeconomically the generic is less expensive ($25/month vs. $40/month for a compounded equivalent). Topical compounded versions serve patients who want localized DHT suppression with potentially lower systemic exposure, though strong clinical data on topical dutasteride absorption and efficacy remain limited. [16]

Patients should verify that the compounding pharmacy holds an active Maine pharmacy license (searchable at the Maine Board of Pharmacy's online license verification tool) and, for higher-complexity sterile preparations, that the pharmacy complies with USP Chapter 797 standards. [17]

Clinical Evidence Supporting Dutasteride for Hair Loss

The FDA approved dutasteride only for BPH, but its use in androgenetic alopecia is supported by peer-reviewed trial data. Eun et al. (J Am Acad Dermatol 2010, N=153) conducted a randomized, double-blind, placebo-controlled trial comparing dutasteride 0.5 mg, 2.5 mg, and finasteride 1 mg daily over 24 weeks in men with androgenetic alopecia. Dutasteride 0.5 mg showed statistically significant improvements in hair count and investigator-assessed hair growth vs. placebo (P<0.001), and outperformed finasteride 1 mg on photographic assessment. [18]

A 2019 meta-analysis published in the Journal of the American Academy of Dermatology reviewed 22 randomized controlled trials of 5-ARIs in androgenetic alopecia and found dutasteride consistently produced greater DHT suppression (90 to 95% vs. 60 to 70% for finasteride 1 mg) due to its dual inhibition of both isoenzymes. Greater DHT suppression at the scalp follicle level correlated with greater hair-count improvements in the trials analyzed. [19]

The Endocrine Society's clinical practice guideline on androgen-related disorders notes that 5-alpha reductase inhibitors carry a class-wide risk of sexual side effects including decreased libido, ejaculatory dysfunction, and erectile dysfunction in 3% to 8% of users, with most effects reversible upon discontinuation. The guideline specifies that patients should be counseled on the PSA reduction artifact: dutasteride suppresses PSA by approximately 50% at 6 months, so baseline PSA should be obtained and subsequent readings doubled for clinical interpretation. [20]

The FDA label for dutasteride notes a small absolute increase in high-grade prostate cancer (Gleason score 7 to 10) observed in the REDUCE trial (N=8,231), with 1.0% of dutasteride subjects vs. 0.5% of placebo subjects developing high-grade disease. This finding does not establish causation and remains under discussion in the urology literature, but it informs the requirement for prostate cancer screening discussion before prescribing. [21]

Telehealth Prescribing of Dutasteride in Maine

Maine allows telehealth prescribing of dutasteride. A licensed Maine prescriber, including physicians, physician assistants, and nurse practitioners with prescriptive authority, may evaluate a patient via synchronous audio-video visit and issue a prescription for dutasteride without an in-person examination, provided the prescriber establishes a valid patient-prescriber relationship and documents clinical appropriateness. [22]

Maine's telehealth parity law (Maine Revised Statutes Title 24-A, Section 4316) requires that commercial insurance reimburse covered telehealth services at parity with in-person services. This does not directly govern prescription costs, but it means the telehealth visit used to obtain a dutasteride prescription is typically a covered benefit under Maine commercial plans and MaineCare. [23]

HealthRX and similar telehealth platforms operating in Maine can prescribe dutasteride after a structured clinical intake that includes prostate cancer risk stratification, baseline PSA documentation for patients over 40, and sexual function baseline assessment. The prescription is transmitted electronically to a pharmacy of the patient's choice, including mail-order pharmacies that serve Maine. [24]

DEA regulations governing controlled substances do not apply to dutasteride; it is not a scheduled drug. That means telehealth prescribing of dutasteride does not require a prior in-person visit under the Ryan Haight Act, and the post-COVID DEA telehealth flexibilities do not affect dutasteride prescribing at all. [25]

How to Get the Cheapest Dutasteride in Maine

The lowest-cost path for most uninsured or underinsured Maine residents follows a four-step decision logic. First, confirm whether your commercial insurance covers generic dutasteride on Tier 1 or Tier 2; if it does, your co-pay is likely $0 to $15 and no further optimization is needed. Second, if uninsured, use a GoodRx Gold or RxSaver coupon at a high-volume pharmacy in a Maine metro area (Portland, Lewiston, Bangor) where dispensing fees are lowest, targeting the $20 to $25 per 30-day range. Third, if you qualify for MaineCare, file the PA for BPH; the $3.65 co-pay beats all other options. Fourth, if your prescriber is using a compounded topical formulation for hair loss, compare the 503A pharmacy's monthly price against the generic oral price before committing.

NeedyMeds maintains a database of patient assistance programs. GSK's Bridges to Access program covers Avodart brand at no cost for patients who meet income criteria (generally at or below 200% of the federal poverty level), though generic availability makes this program less commonly needed. GSK's program can be reached at 1-888-825-5249. [26]

Maine's Section 340B program applies to federally qualified health centers (FQHCs) across the state, including Community Health and Counseling Services, Penobscot Community Health Care, and others. Patients who receive primary care at a 340B-participating FQHC may access dutasteride at the deeply discounted 340B ceiling price, which is typically below even the generic cash-pay price. The HRSA 340B database lists eligible entities by ZIP code. [27]

For 90-day supplies, mail-order pharmacies such as Costco Pharmacy (open to non-members for pharmacy services in Maine), Mark Cuban's Cost Plus Drugs, and Amazon Pharmacy frequently beat retail 30-day pricing. Cost Plus Drugs lists generic dutasteride 0.5 mg at approximately $17 for a 90-day supply as of early 2025, which annualizes to under $70 per year. [28]

Dosing, Administration, and What Maine Prescribers Typically Order

The FDA-approved dose of dutasteride for BPH is 0.5 mg taken orally once daily. The capsule should be swallowed whole; it must not be crushed or chewed because the liquid inside can irritate oral mucosa and because dutasteride is absorbed through skin, posing a risk to pregnant women who handle broken capsules. [29]

Steady-state DHT suppression occurs at approximately 1 to 2 weeks, but the clinical benefits for BPH symptom scores typically emerge at 3 to 6 months, and maximum prostate volume reduction takes 6 to 12 months. For hair loss, visible density improvements in responders generally appear at 6 months and continue through 24 months. [30]

For androgenetic alopecia, some Maine prescribers write for 0.5 mg daily (the BPH dose), while others follow data from the Eun 2010 trial using the same 0.5 mg dose. A minority of clinicians use 0.25 mg daily (a compounded strength) to reduce systemic DHT suppression while retaining scalp-level benefit, though this dose-response relationship has not been established in large RCTs. [18]

Serum PSA should be checked at baseline in men over 40 before starting dutasteride, and again at 3 to 6 months. The AUA guideline on BPH states: "A PSA less than 1.4 ng/mL after 6 months of 5-ARI therapy should prompt further evaluation, as it may suggest treatment nonadherence or an underlying prostatic malignancy." [31]

Drug interactions are limited. Dutasteride is metabolized by CYP3A4; potent CYP3A4 inhibitors (ketoconazole, ritonavir) can raise dutasteride plasma concentrations, though dose adjustments are not established in the label. Co-administration with tamsulosin 0.4 mg (the CombAT trial regimen, N=4,844) is a well-studied and guideline-supported combination for moderate-to-severe BPH. [32]

Side Effects and Monitoring Maine Patients Should Know

Sexual side effects are the most commonly reported adverse events. The REDUCE trial (N=8,231, dutasteride 0.5 mg vs. placebo, 4-year follow-up) reported decreased libido in 3.1% of dutasteride subjects vs. 1.8% placebo, erectile dysfunction in 4.9% vs. 3.3%, and ejaculatory disorders in 1.4% vs. 0.5%. Most events occurred in the first 6 months of treatment. [21]

Post-finasteride syndrome (PFS) has been described anecdotally following 5-ARI use, and similar reports exist for dutasteride. The FDA added a label update in 2012 noting that sexual side effects may persist after discontinuation in some patients. A dermatology consensus statement from the International Society of Hair Restoration Surgery acknowledges the phenomenon while noting that the incidence of persistent effects is difficult to quantify from existing RCT data. [33]

Breast tenderness and gynecomastia affect roughly 1% to 2% of long-term users, as documented in the REDUCE trial data and the CombAT trial. Any new breast mass requires evaluation to rule out male breast cancer, a rare but documented risk that the FDA label explicitly flags. [32]

Liver function abnormalities are rare. The FDA label does not require routine hepatic monitoring, but clinicians managing patients with pre-existing hepatic impairment should use dutasteride with caution given that the drug is extensively hepatically metabolized and has a half-life of 3 to 5 weeks. [29]